ANAVEX LIFE SCIENCES CORP.
AVXLNasdaq
$2.39
↑ +2.1%Jul 17 close · end-of-day
Price
1Y↓ -78.8%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$212.8M
Enterprise Value
$81.0M
P/E
—
P/S
—
P/B
1.7
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$39.9M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-31.6%
ROIC
—
Debt / Equity
—
Net Cash
$131.7M
Return 1Y
-78.4%
Company profile
Anavex Life Sciences Corp. engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the. treatment of Alzheimer's disease. The company's drug candidate also comprises ANaVEX 3-71 which is. in Phase I clinical. trial for frontotemporal dementia and other dementia indications.
- CEO
- Christopher U. Missling
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 40
- Headquarters
- New York
- Website
- anavex.com
Earnings
AVXL Q1 2025 Earnings
Period ends 2025-12-31
MetricActualYoY
Revenue——
Diluted EPS-$0.06↓ -57.1%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$31.1M | -$42.0M | -$51.0M | -$55.8M | -$52.9M | -$51.4M |
| Net income | -$26.3M | -$37.9M | -$48.0M | -$47.5M | -$43.0M | -$46.4M |
| Diluted EPS | — | -$0.54 | -$0.62 | -$0.60 | -$0.52 | -$0.54 |
| Operating cash flow | -$21.3M | -$30.4M | -$24.2M | -$27.8M | -$30.8M | -$39.0M |
| Free cash flow | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '24 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '25 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$12.6M | -$14.6M | -$14.3M | -$13.6M | -$12.5M | -$14.5M | -$10.8M | -$6.8M |
| Net income | -$10.5M | -$12.2M | -$11.6M | -$12.1M | -$11.2M | -$13.2M | -$9.8M | -$5.7M |
| Diluted EPS | -$0.13 | -$0.14 | -$0.14 | -$0.14 | -$0.13 | -$0.16 | -$0.11 | -$0.06 |
| Operating cash flow | -$11.7M | -$5.2M | -$6.7M | -$12.1M | -$5.9M | -$12.5M | -$8.6M | -$7.2M |
| Free cash flow | — | — | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
May 22, 2026
May 6, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2025-09-11 | MISSLING CHRISTOPHER U· President and CEO | Tax withholding | 145,048 | $9.58 | $1.4M | filing |
| 2025-09-11 | MISSLING CHRISTOPHER U· President and CEO | Option exercise | 187,500 | $5.04 | $945,000.00 | filing |
Latest 2 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.